Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
N/A
1(33.3%)
3Total
Phase 4(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05004246Enrolling By Invitation

Longitudinal Changes in Characteristics of COVID-19 Survivors and Their Long-term Follow-up Study

Role: collaborator

NCT04972591Unknown

Follow-up Study of Population Vaccinated With COVID-19 Vaccine

Role: collaborator

NCT02945163Phase 4Completed

Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy

Role: collaborator

NCT02935075Phase 4Completed

Optimization of Antiretroviral Therapy

Role: collaborator

NCT03478033Not ApplicableUnknown

Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis

Role: collaborator

All 5 trials loaded